Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inebilizumab for the Treatment of Patients With Relapsing Type 1 Autoimmune Pancreatitis: A Multicenter, Single-Arm, Open-Label Study

NCT07862075 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07862075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07862075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inebilizumab for the Treatment of Patients With Relapsing Type 1 Autoimmune Pancreatitis: A Multicenter, Single-Arm, Open-Label Study
Lead sponsor
Ruijin Hospital
Phase
Phase 4
Overall status
Recruiting
Start date
October 1, 2025
Completion date
September 30, 2028
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

type 1 aip